GFAP positive CD9+ exosomes of total CD9+ exosomes were 7.9 times higher in patients with recurrent glioma (22.8%; 18.2–27.1%) compared to healthy controls (2.9%; 2.7–3.2%) at baseline. This evidence concerns the gene CD9 and central nervous system cancer.